Roos Verstegen

Ms. Roos Verstegen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
RVRoos Verstegen
Roos Verstegen
AKAtanaska Kostadinova
Atanaska Kostadinova
ZMZenebech Merenciana
Zenebech Merenciana
JGjohan Garssen
johan Garssen
GFGert Folkerts
Gert Folkerts
LWLinette E.M. Willemsen
Linette E.M. Willemsen
The prevalence of asthma is increasing, but the cause remains under debate. Research currently focuses on environmental and dietary factors that may impact the gut-lung axis. Dietary fibers are considered to play a crucial role in supporting diversity and activity of the microbiome, as well as immune homeostasis in the gut and lung. This review discusses the current state of knowledge on how dietary fibers and their bacterial fermentation products may affect the pathophysiology of allergic asthma. Moreover, the impact of dietary fibers on early type 2 asthma management, as shown in both pre-clinical and clinical studies, is described. Short-chain fatty acids, fiber metabolites, modulate host immunity and might reduce the risk of allergic asthma development. Underlying mechanisms include G protein-coupled receptor activation and histone deacetylase inhibition. These results are supported by studies in mice, children and adults with allergic asthma. Fibers might also exert direct effects on the immune system via yet to be elucidated mechanisms. However, the effects of specific types of fiber, dosages, duration of treatment, and combination with probiotics, need to be explored. There is an urgent need to further valorize the potential of specific dietary fibers in prevention and treatment of allergic asthma by conducting more large-scale dietary intervention trials.

4 August 2025 in Clinical and Translational Allergy
Verified
Journal Article
Open access
RVRoos Verstegen
Roos Verstegen
RSRolf W. Sparidans
Rolf W. Sparidans
AKAtanaska I. Kostadinova
Atanaska I. Kostadinova
JGjohan Garssen
johan Garssen
GFGert Folkerts
Gert Folkerts
LWLinette E. M. Willemsen
Linette E. M. Willemsen
Aims: Microbial dysbiosis is an important feature in allergic asthma. Short‐chain fatty acids (SCFA) produced by the intestinal microbiome play a role in the gut‐lung axis. Little is known about how the gut SCFA levels reflect SCFA levels in other tissues and how these link to the allergic asthma inflammatory status.Materials and Methods: Male BALB/c mice were intranasally exposed to house dust mite (HDM) to induce allergic airway inflammation. Acetate, propionate, and butyrate levels were determined in caecum content, serum and lungs of control and HDM‐allergic mice using liquid chromatography‐mass spectrometry. Faecal microbiome composition was determined by DNA sequencing.Results: Mean acetate:propionate:butyrate ratios were 75:15:10 in caecum content, 98:1.5:0.5 in serum, and 38:61:1 in the lung. SCFA levels did not correlate across compartments and propionate was relatively high in the lungs. The faecal microbiome of allergic mice differed from control, with increased Desulfovibrionaceae abundance. The lung acetate proportion was lower in allergic mice compared to control. In allergic mice, declining lung acetate levels correlated with increased HDM‐specific IgE in serum and IL‐13 release by ex vivo HDM‐restimulated lung cells. Ex vivo acetate supplementation did not inhibit HDM‐restimulated lung cell IL‐13 production, while butyrate and propionate did.Conclusions: Overall, HDM‐driven murine allergic airway inflammation induced changes in the faecal microbiome and reduced acetate in serum and lung tissue. Hereby, lung acetate levels correlated negatively with sensitisation and type‐2 inflammation, but acetate itself did not suppress ex vivo HDM‐induced cytokine release. Our findings provide new insights on the systemic effects of HDM‐allergic inflammation along the gut‐lung axis.

11 November 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
RVRoos Verstegen
Roos Verstegen
MZMarit Zuurveld
Marit Zuurveld
STSuzan Thijssen
Suzan Thijssen
MBMarjolein de Bruijn
Marjolein de Bruijn
IAIngrid van Ark
Ingrid van Ark
LWLinette E.M. Willemsen
Linette E.M. Willemsen
Background/Objectives: The gut microbiome has an important role in immune regulation, and dietary interventions that support a balanced microbiota may help to prevent the development of allergic asthma. Dietary fibers can beneficially affect the intestinal microbiome, but due to the diversity of fiber types, the effects differ. In this study, we investigate the preventive effects of two mixes of short-chain and long-chain (1:1 and 9:1 ratio) fructo-oligosaccharides (FOS) in a mouse model of house dust mite (HDM)-induced allergic asthma. Methods: BALB/c mice received FOS-supplemented (1% w/w) diets before and during intranasal exposures to HDM. Endpoint airway hyperreactivity measurements were performed, followed by the collection of bronchoalveolar lavage fluid (BALF), lung, serum and cecum content. Fecal microbiome composition was determined by DNA sequencing and short-chain fatty acid (SCFA) levels were determined in the cecum, serum and lung. Results: Fecal microbiome analyses revealed an increased abundance of Prevotellaceae after FOS1:1 supplementation in HDM-allergic mice. Additionally, FOS1:1 protected against an HDM-induced increase in basal airway resistance. Both FOS1:1 and FOS9:1 restored the systemic acetate levels in HDM-allergic mice. The two FOS supplementations did not affect HDM-induced inflammatory cell influx in the BALF. However, FOS1:1 increased the frequency of Th1-cells and prevented an HDM-induced increase in the Th2/Th1 balance. Upon ex vivo restimulation with HDM, lung cell suspensions of FOS1:1-fed mice produced less type 2-related cytokines compared to control-supplemented mice, and FOS9:1 followed a similar pattern. Conclusions: Specific short-chain and long-chain FOS ratios differentially affect the microbiome and immune system in a mouse model with HDM-induced allergic airway inflammation. Dietary supplementation with FOS1:1 shifts the immune response away from type 2, suggesting that dietary fibers like FOS1:1 may contribute as a part of a broader strategy to modulate HDM-induced allergic asthma.

21 November 2025
Verified
Thesis
Closed access
RVRoos Verstegen
Roos Verstegen
Allergic asthma is a chronic lung disease that affects millions of people worldwide. It is often triggered by allergens such as house dust mite and leads to lung inflammation and breathing difficulties. This dissertation investigated whether dietary fibers, specifically fructo-oligosaccharides (FOS) found in fruits, vegetables, and grains, can help reduce asthma-like symptoms. The underlying hypothesis is that FOS can influence the gut microbiota, and that beneficial gut bacteria can ferment FOS into short-chain fatty acids (SCFAs)—acetate, propionate, and butyrate—that may suppress airway inflammation. The research program combined in vitro cell culture studies using human lung epithelial cells with a model for allergic asthma in mice. The in vitro studies demonstrated that butyrate could protect bronchial epithelial cells against barrier damage and inflammatory signals induced by house dust mite exposure. In mice, it was observed that the balance of SCFAs differs across body compartments such as the gut, blood, and lungs, with lung-specific acetate levels being particularly reduced in allergic asthma. In house dust mite-allergic mice, the effects of dietary supplementation with two ratios of short- and long-chain FOS, as well as different FOS dosages, were assessed on allergic airway inflammation. Results showed that FOS, depending on ratio and dose, could alter gut microbiota composition, modulate SCFA levels, and shift immune responses, thereby reducing type 2 allergic inflammation. However, even the highest FOS dose (10%) could not prevent allergic airway inflammation. This dissertation demonstrates that FOS can influence gut microbiota, immune responses, and lung health. Although FOS did not prevent development of house dust mite-induced asthma, it did protect against allergic type 2 immune activation. FOS supplementation therefore warrants further investigation as a potential supportive strategy in the management of allergic asthma. This work also highlights the importance of a fiber-rich diet in supporting the microbiome, immune system, and respiratory function.

26 March 2026 in Respiratory Research
Verified
Journal Article
Open access
RVRoos Verstegen
Roos Verstegen
STSuzan Thijssen
Suzan Thijssen
AKAtanaska I. Kostadinova
Atanaska I. Kostadinova
JGjohan Garssen
johan Garssen
GFGert Folkerts
Gert Folkerts
LWLinette E.M. Willemsen
Linette E.M. Willemsen
The online version contains supplementary material available at 10.1186/s12931-026-03563-z. The online version contains supplementary material available at 10.1186/s12931-026-03563-z.

19 May 2026 in Respiratory Research
Verified
Journal Article
Open access
RVRoos Verstegen
Roos Verstegen
JHJennifer Hotie
Jennifer Hotie
MBMargarita Bikineeva
Margarita Bikineeva
SBSuze van Brummelen
Suze van Brummelen
JGjohan Garssen
johan Garssen
LWLinette E.M. Willemsen
Linette E.M. Willemsen
The airway epithelial barrier is the primary defense line of the lungs against allergens, such as house dust mite (HDM). A disrupted airway epithelial barrier plays a major role in asthma development. Short-chain fatty acids (SCFAs) are bacterial fermentation products that are associated with prevention against allergic inflammation. In this study, we aim to elucidate the direct preventative effects of SCFAs, particularly butyrate, on the HDM-induced bronchial epithelial cell (BEC) activation and barrier disruption in-vitro. Immortalized human 16HBE cells were exposed to HDM to simulate allergen-induced BEC inflammation. Pre-exposure of 1-1000 µM acetate, propionate or butyrate were studied for their ability to prevent epithelial activation. Histone deacetylase activity of cells was measured after pre-incubation with 100 or 200 µM butyrate and combined butyrate and HDM exposure. In a transwell, air-liquid interface (ALI)-culture, the effects of 100 µM butyrate on barrier integrity (transepithelial resistance (TEER) and 4 kDa FITC-dextran permeability) and inflammation were assessed in presence and absence of HDM. To gain broader insight in the effects of butyrate, RNA sequencing (RNAseq) was performed using 16HBE cells exposed to HDM, butyrate or both. Pre-incubation with butyrate protected against the production of HDM-induced IL-8 (1-100 µM), CCL5 (1-100-1000 µM) and CCL20 (1-10-100 µM) by solid phase cultured 16HBE-cells, although 1000 µM butyrate increased IL-8 and CCL20 release. Pre-incubation with acetate and propionate showed similar effects. 100 µM butyrate did not suppress HDAC activity, while a dose of 200 µM butyrate did. In ALI-culture, HDM increased barrier permeability, and pre-incubation with 100 µM butyrate tended to prevent this. Additionally, HDM-induced CCL20 production was significantly decreased by butyrate. RNAseq revealed 100 µM butyrate to significantly affect biological processes of the cells linked to gene expression, mitochondrial function, cell division and cell signaling. These effects were observed both in absence and presence of HDM-exposure. Butyrate, at physiologically relevant doses, modulates gene expression of 16HBE cells, affecting amongst others post-transcriptional and mitochondrial pathways. In ALI-cultures, butyrate prevented epithelial activation (CCL20) and tended to prevent HDM-induced barrier defects. These findings highlight the relevance of SCFAs such as butyrate in maintaining bronchial epithelial cell homeostasis relevant for prevention and control of allergic airway disease.